亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study

耐受性 间充质干细胞 队列 临床试验 不利影响 医学 内科学 诱导多能干细胞 药理学 间质细胞 病理 生物 生物化学 基因 胚胎干细胞
作者
Adrian John Clifton Bloor,Amit Patel,James E. Griffin,Maria Helena Gilleece,Rohini Radia,David T. O. Yeung,Diana Drier,Laurie S. Larson,Gene I. Uenishi,Derek J. Hei,Kilian Kelly,Igor I. Slukvin,John E. J. Rasko
出处
期刊:Nature Medicine [Nature Portfolio]
卷期号:26 (11): 1720-1725 被引量:293
标识
DOI:10.1038/s41591-020-1050-x
摘要

The therapeutic potential of donor-derived mesenchymal stromal cells (MSCs) has been investigated in diverse diseases1, including steroid-resistant acute graft versus host disease (SR-aGvHD)2. However, conventional manufacturing approaches are hampered by challenges with scalability and interdonor variability, and clinical trials have shown inconsistent outcomes3,4. Induced pluripotent stem cells (iPSCs) have the potential to overcome these challenges, due to their capacity for multilineage differentiation and indefinite proliferation5,6. Nonetheless, human clinical trials of iPSC-derived cells have not previously been completed. CYP-001 (iPSC-derived MSCs) is produced using an optimized, good manufacturing practice (GMP)-compliant manufacturing process. We conducted a phase 1, open-label clinical trial (no. NCT02923375) in subjects with SR-aGvHD. Sixteen subjects were screened and sequentially assigned to cohort A or cohort B (n = 8 per group). One subject in cohort B withdrew before receiving CYP-001 and was excluded from analysis. All other subjects received intravenous infusions of CYP-001 on days 0 and 7, at a dose level of either 1 × 106 cells per kg body weight, to a maximum of 1 × 108 cells per infusion (cohort A), or 2 × 106 cells per kg body weight, to a maximum dose of 2 × 108 cells per infusion (cohort B). The primary objective was to assess the safety and tolerability of CYP-001, while the secondary objectives were to evaluate efficacy based on the proportion of participants who showed a complete response (CR), overall response (OR) and overall survival (OS) by days 28/100. CYP-001 was safe and well tolerated. No serious adverse events were assessed as related to CYP-001. OR, CR and OS rates by day 100 were 86.7, 53.3 and 86.7%, respectively. The therapeutic application of iPSC-derived MSCs may now be explored in diverse inflammatory and immune-mediated diseases.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
聪慧亦凝发布了新的文献求助10
1秒前
沉疴能自痊完成签到 ,获得积分10
3秒前
李月完成签到 ,获得积分10
4秒前
科研通AI65的应助被萧雨墨采纳,获得30
7秒前
zhangzhang发布了新的文献求助10
7秒前
7秒前
ch完成签到,获得积分10
8秒前
小蘑菇的应助被沧海云帆采纳,获得10
11秒前
ZT1发布了新的文献求助10
13秒前
amiee发布了新的文献求助10
14秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
15秒前
Nole的应助被科研通管家采纳,获得10
15秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
15秒前
15秒前
Nole的应助被科研通管家采纳,获得10
15秒前
Nole的应助被科研通管家采纳,获得10
15秒前
852的应助被科研通管家采纳,获得10
15秒前
16秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
16秒前
16秒前
18秒前
19秒前
乐乐的应助被zhangzhang采纳,获得10
19秒前
娜娜米发布了新的文献求助80
21秒前
沧海云帆发布了新的文献求助10
23秒前
24秒前
26秒前
27秒前
pzh完成签到 ,获得积分10
29秒前
31秒前
34秒前
41秒前
笨笨的青完成签到 ,获得积分10
41秒前
冷酷的飞绿完成签到 ,获得积分10
41秒前
Crssss的应助被优雅的黄豆采纳,获得10
41秒前
41秒前
小二郎的应助被娜娜米采纳,获得10
43秒前
张唤发布了新的文献求助10
45秒前
尊敬的之瑶完成签到,获得积分20
45秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190049
求助须知:如何正确求助?哪些是违规求助? 9577165
关于积分的说明 21851842
捐赠科研通 7788131
什么是DOI,文献DOI怎么找? 3436227
关于科研通互助平台的介绍 2559910
邀请新用户注册赠送积分活动 2482768